Lantern Pharma Advances Rare Pediatric Brain Cancer Treatment Using AI Platform
Lantern Pharma is preparing clinical trials for a rare pediatric brain cancer treatment using its AI-powered RADR platform, following positive FDA feedback on trial design and regulatory pathways.
Lantern Pharma Inc. (NASDAQ: LTRN) is advancing clinical development for a rare pediatric brain cancer treatment using its proprietary computational biology and machine learning platform. The company is preparing to launch a trial targeting central nervous system cancers in children, scheduled for Q1 2026, following constructive discussions with the U.S. Food and Drug Administration regarding trial design and regulatory pathways.
The investigational therapy LP-184/STAR-001 is designed to combat Atypical Teratoid Rhabdoid Tumor and other CNS cancers through synergistic action with diuretic spironolactone and potential combination regimens. Lantern's program has received both Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, positioning the company to submit an investigational new drug amendment in the near future.
Lantern President and CEO Panna Sharma expressed enthusiasm about the FDA feedback, noting that the guidance reinforces the company's trial design while highlighting the potential of the RADR AI platform in identifying and optimizing combination treatments for devastating pediatric CNS cancers. The company's AI-driven approach represents a significant advancement in oncology drug development methodology.
The RADR platform leverages over 200 billion oncology-focused data points and more than 200 machine learning algorithms to accelerate drug discovery and development. This computational approach has enabled Lantern to advance new drug programs from initial AI insights to first-in-human clinical trials in just 2-3 years at approximately $2.5 million per program, significantly reducing both time and cost compared to traditional drug development methods.
For additional information about Lantern Pharma's developments, visit https://ibn.fm/LTRN. The company's progress in pediatric oncology treatment development demonstrates how artificial intelligence is transforming cancer drug discovery and addressing unmet medical needs in rare diseases.